Moleculin management & industry KOLs discussed the announced positive interim data for Annamycin from our ongoing #AML clinical development program, highlighting the reported higher AML CR rates with additional interim subject data. Watch the replay: bit.ly/3JPEfPH $MBRX

The NIH-funded, investigator-initiated Phase 2 clinical trial combines WP1066 and radiation, which demonstrated both significant therapeutic response and immune “memory” in #glioblastoma animal models. Learn more: bit.ly/3UWWlpn $MBRX #GBM

ICYMI: Moleculin recently hosted a Virtual AML Clinical Day to discuss the #AML treatment landscape as well as the positive interim data for Annamycin from our ongoing #AcuteMyeloidLeukemia clinical development program. Watch the replay: bit.ly/3JPEfPH $MBRX

Moleculin today announced its abstract has been accepted for poster presentation at the European Hematology Association Hybrid Congress being held June 13-16, 2024 in Madrid, Spain and virtually. For details: bit.ly/4bkjJ5V $MBRX #EHA2024

Dr. Priya Kumthekar & Dr. Amy Heimberger comment on the potential of WP1066 in combination with radiation therapy for the treatment of #GBM . Learn about the investigator-initiated Ph. 2 study conducted at Northwestern in cooperation with Moleculin: bit.ly/3UWWlpn $MBRX

Moleculin announced the commencement of an investigator-initiated Ph. 2 study evaluating WP1066 in combination with radiation therapy for the treatment of adults with #GBM . The NIH-funded study is being conducted at Northwestern in cooperation with $MBRX bit.ly/3UWWlpn

Tune-in today, May 13th at 8:30 AM ET for a conference call and live audio webcast hosted by Moleculin to discuss its Q1 2024 operational and financial results. For details: bit.ly/3WuP80Y $MBRX

Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update bit.ly/4dwmaE9 $MBRX

Our CEO Walter Klemp comments on the announced U.S. Patent Issue Notification for lipid-based delivery technology for Annamycin. The patent, once issued, will further strengthen Moleculin’s composition of matter protection for Annamycin. Learn more: bit.ly/44wHS6N $MBRX

Moleculin has received an Issue Notification from the USPTO for U.S. Patent number 11,980,634 titled, “Method of Reconstituting Liposomal Annamycin” to be issued on May 14, 2024 to Moleculin and The University of Texas System Board of Regents. bit.ly/44wHS6N $MBRX

Moleculin will report its financial results for the quarter ended March 31, 2024, on Friday, May 10th. Management will host a conference call and live audio webcast to discuss the operational and financial results at 8:30 AM ET on Monday, May 13th. bit.ly/3WuP80Y $MBRX

Our CEO Walter Klemp comments on the positive interim data for Annamycin from Moleculin's ongoing #AML clinical development program, highlighting the reported higher AML complete remission (CR) rates with additional interim subject data: bit.ly/4acGtn7 $MBRX

Tune-in today at 11 AM ET for Moleculin's virtual AML Clinical Day! Learn about the unmet medical needs in the treatment of #AcuteMyeloidLeukemia , Annamycin and Moleculin's #AML clinical development program as well as data demonstrated to date. bit.ly/3JPEfPH $MBRX

Moleculin announced the presentation of positive interim data for Annamycin from its ongoing #AML clinical development program. The Company will host a virtual AML Clinical Day, today, May 7, at 11 AM ET to discuss these results. For more info: bit.ly/4acGtn7 $MBRX

We will host a virtual AML Clinical Day on May 7 to discuss the treatment landscape for AML & how Annamycin is positioned to address a significant unmet medical need, as well as the Annamycin AML data demonstrated to date with a KOL in the AML space. bit.ly/3y3h4yZ $MBRX

Our CEO Walter Klemp comments on the formation of its Scientific Advisory Board to support the development of Annamycin. For more: bit.ly/4dlL0pV $MBRX

Moleculin will host a virtual AML Clinical Day with an industry KOL on Tuesday, May 7th at 11 AM ET to discuss the unmet medical needs in the treatment of #AcuteMyeloidLeukemia , Annamycin and the Company’s #AML clinical development program. For details: bit.ly/3y3h4yZ

Moleculin today announced the formation of its Annamycin Scientific Advisory Board. Learn more: bit.ly/4dlL0pV $MBRX

Have you seen the three-part series of our CEO, Wally Klemp, emphasizing the Moleculin opportunity? Check them out here: bit.ly/3jNmovI

$MBRX #Oncology #AcuteMyeloidLeukemia #STSLungMets

Watch the Virtual Investor Co. “What This Means” segment featuring Moleculin's CEO Walter Klemp to learn about the Company’s next-generation anthracycline, Annamycin, and how it compares with highly valued assets in the #AcuteMyeloidLeukemia space: bit.ly/3JFnEhm $MBRX #AML